The renaissance of polymyxins

Current Medicinal Chemistry

Volumn 20, Issue 30, 2013, Pages 3759-3773

  Kadar, B ^a   Kocsis, B ^a   Nagy, K ^a   Szabo, D ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Antimicrobial activity; Colistin; Mechanism of action; Polymyxin B; Polymyxin derivatives; Structure activity relationship; Toxicity

Indexed keywords

ANTIINFECTIVE AGENT; BENZYL DERIVATIVE; BENZYLIDENE DERIVATIVE; COLISTIN; COTRIMOXAZOLE; DORIPENEM; FLUCONAZOLE; HEPTAPEPTIDE; NAB 7061; NAB 734; NAB 735; NAB 737; NAB 739; NAB 740; NAB 741; POLYMYXIN B; POLYMYXIN B NONAPEPTIDE; POLYMYXIN DERIVATIVE; POLYMYXIN M; POLYMYXIN S; POLYMYXIN T; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ATAXIA; BRONCHOSPASM; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEST TIGHTNESS; CONFUSION; CONTACT DERMATITIS; COUGHING; CREATININE BLOOD LEVEL; DRUG HALF LIFE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HALLUCINATION; HEMATURIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OLIGURIA; PARESTHESIA; PROTEINURIA; PRURITUS; RASH; SEIZURE; SIDE EFFECT; SORE THROAT; STRUCTURE ACTIVITY RELATION; URTICARIA; VERTIGO;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; DRUG DISCOVERY; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMYXINS;

EID: 84883382208     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990185     Document Type: Article

References (117)

1. Ainsworth, G.C.; Brown, A.M.; Brownlee, G. Aerosporin, an antibiotic produced by Bacillus aerosporus Greer. Nature, 1947, 159(4060), 263.
2. Brownlee, G.; Bushby, S.R. Chemotherapy and pharmacology of aerosporin; a selective Gram-negative antibiotic. Lancet, 1948, 1(6491), 127-132.
3. Koch-Weser, J.; Sidel, V.W.; Federman, E.B.; Kanarek, P.; Finer, D.C.; Eaton, A.E. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med., 1970, 72(6), 857-868.
4. Souli, M.; Galani, I.; Giamarellou, H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Eur. Surveill., 2008, 13(47), pii: 19045.
5. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis., 2009, 48(1), 1-12.
6. Giamarellou, H.; Poulakou, G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs, 2009, 69(14), 1879-1901.
7. Giamarellou, H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int. J. Antimicrob. Agents, 2010, 36 Suppl 2, S50-S54.
8. Li, J.; Nation, R.L.; Turnidge, J.D.; Milne, R.W.; Coulthard, K.; Rayner, C.R.; Paterson, D.L. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis., 2006, 6(9), 589-601.
9. Landman, D.; Georgescu, C.; Martin, D.A.; Quale, J. Polymyxins revisited. Clin. Microbiol. Rev., 2008, 21(3), 449-465.
10. Michalopoulos, A.S.; Falagas, M.E. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann. Intensive Care, 2011, 1(1), 30.
11. Michalopoulos, A.S.; Karatza, D.C.; Gregorakos, L. Pharmacokinetic evaluation of colistin sodium. Expert Opin. Drug Metab. Toxicol., 2011, 7(2), 245-255.
12. Couet, W.; Gregoire, N.; Marchand, S.; Mimoz, O. Colistin pharmacokinetics: the fog is lifting. Clin. Microbiol. Infect., 2012, 18(1), 30-39.
13. Urban, C.; Mariano, N.; Rahal, J.J. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob. Agents Chemother., 2010, 54(6), 2732-2734.
14. Humphries, R.M.; Kelesidis, T.; Dien Bard, J.; Ward, K.W.; Bhattacharya, D.; Lewinski, M.A. Successful treatment of panresistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin. J. Med. Microbiol., 2010, 59(Pt 11), 1383-1386.
15. Mitsugui, C.S.; Tognim, M.C.; Cardoso, C.L.; Carrara-Marroni, F.E.; Botelho Garcia, L. In vitro activity of polymyxins in combination with β-lactams against clinical strains of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents, 2011, 38(5), 447-450.
16. Vaara, M.; Fox, J.; Loidl, G.; Siikanen, O.; Apajalahti, J.; Hansen, F.; Frimodt-Møller, N.; Nagai, J.; Takano, M.; Vaara, T. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob. Agents Chemother., 2008, 52(9), 3229-3236.
17. Vaara, M.; Vaara, T. Structure-activity studies on novel polymyxin derivatives that carry only three positive charges. Peptides, 2010, 31(12), 2318-2321.
18. Mingeot-Leclercq, M.P.; Tulkens, P.M.; Denamur, S.; Vaara, T.; Vaara, M. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides, 2012, 35(2), 248-252.
19. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12th ed. Brunton, L.L.; Chabner, B.A.; Knollmann, B.C., Eds.; The McGraw-Hill Companies, Inc., 2011, pp 1538-1539.
20. Komura, S.; Kurahashi, K. Biosynthesis of polymyxin E. III. Total synthesis of polymyxin E by a cell-free enzyme system. Biochem. Biophys. Res. Commun., 1980, 95(3), 1145-1151.
21. Choi, S.K.; Park, S.Y.; Kim, R.; Kim, S.B.; Lee, C.H.; Kim, J.F.; Park, S.H. Identification of a polymyxin synthetase gene cluster of Paenibacillus polymyxa and heterologous expression of the gene in Bacillus subtilis. J. Bacteriol., 2009, 191(10), 3350-3358.
22. Storm, D.R.; Rosenthal, K.S.; Swanson, P.E. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem., 1977, 46, 723-763.
23. Skiada, A.; Markogiannakis, A.; Plachouras, D.; Daikos, G.L. Adaptive resistance to cationic compounds in Pseudomonas aeruginosa. Int. J. Antimicrob. Agents, 2011, 37(3), 187-193.
24. Catch, J.R.; Jones, T.S. The chemical nature of aerosporin; isolation of a new natural amino-acid. Biochem. J., 1948, 42(4), lii.
25. Jones, T.S. The chemical nature of aerosporin. Biochem. J., 1948, 42(2), xxxv.
26. Jawetz, E.; Coleman, V.R. Laboratory and clinical observations on aerosporin (polymyxin B). J. Lab. Clin. Med., 1949, 34(6), 751-760.
27. Vaara, M. Polymyxins and their novel derivatives. Curr. Opin. Microbiol., 2010, 13(5), 574-581.
28. Kalász, H.; Horváth, C. Preparative-scale separation of polymyxins with an analytical high-performance liquid chromatography system by using displacement chromatography. J. Chromatogr. A., 1981, 215, 295-302.
29. Orwa, J.A.; Govaerts, C.; Busson, R.; Roets, E.; Van Schepdael, A.; Hoogmartens, J. Isolation and structural characterization of colistin components. J. Antibiot. (Tokyo), 2001, 54(7), 595-599.
30. Orwa, J.A.; Govaerts, C.; Busson, R.; Roets, E.; Van Schepdael, A.; Hoogmartens, J. Isolation and structural characterization of polymyxin B components. J. Chromatogr. A., 2001, 912(2), 369-373.
31. Kucers, A.; Crowe, S.; Grayson, M.L.; Hoy, J. In The Use of Antibiotics, 5th ed. Kucers, A.; Crowe, S.; Grayson, M.L.; Hoy, J., Eds.; Butterworth-Heinemann: Oxford, 1997, pp 667-675.
32. Falagas, M.E.; Kasiakou, S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis., 2005, 40(9), 1333-1341.
33. Loutet, S.A.; Valvano, M.A. Extreme antimicrobial peptide and polymyxin B resistance in the genus Burkholderia. Front. Microbiol., 2011, 2, 159.
34. Silaev, A.B.; Trifonova, Z.P.; Maevskaya, S.N.; Vasil'eva, N.M.; Katrukha, G.S. The structure of the antibiotic polymyxin M. Chem. Nat. Compd., 1975, 9(2), 278-279.
35. Trakhanova, M.N.; Zinchenko, A.A.; Bairamashvili, D.I.; Makarova, R.A.; Samoilova, L.N.; Miroshnikov, A.I. [Structural and functional investigation of polymyxins. Isolation and properties of individual components of polymyxin M]. Antibiot. Khimioter., 1988, 33(4), 262-266.
36. Trakhanova, M.N.; Zinchenko, A.A.; Okhanov, V.V.; Dubovsky, P.V.; Bairamashvili, D.I.; Miroshnikov, A.I.; Samoilova, L.N.; Fomina, I.P. [Structural and functional investigation of polymyxins. Structure and biological properties of polymyxin M analogs]. Antibiot. Khimioter., 1989, 34(1), 20-24.
37. Martin, N.I.; Hu, H.; Moake, M.M.; Churey, J.J.; Whittal, R.; Worobo, R.W.; Vederas, J.C. Isolation, structural characterization, and properties of mattacin (polymyxin M), a cyclic peptide antibiotic produced by Paenibacillus kobensis M. J. Biol. Chem., 2003, 278(15), 13124-13132.
38. Shoji, J.; Kato, T.; Hinoo, H. The structure of polymyxin S1 (Studies on antibiotics from the genus Bacillus. XXI). J. Antibiot. (Tokyo), 1977, 30(12), 1035-1041.
39. Shoji, J.; Kato, T.; Hinoo, H. The structure of polymyxin T1 (Studies on antibiotics from the genus Bacillus. XXII). J. Antibiot. (Tokyo), 1977, 30(12), 1042-1048.
40. Vaara, M.; Vaara, T. Polycations sensitize enteric bacteria to antibiotics. Antimicrob. Agents Chemother., 1983, 24(1), 107-113.
41. Vaara, M.; Vaara, T. Sensitization of Gram-negative bacteria to antibiotics and complement by a nontoxic oligopeptide. Nature, 1983, 303(5917), 526-528.
42. Viljanen, P.; Vaara, M. Susceptibility of Gram-negative bacteria to polymyxin B nonapeptide. Antimicrob. Agents Chemother., 1984, 25(6), 701-705.
43. Warren, H.S.; Kania, S.A.; Siber, G.R. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob. Agents Chemother., 1985, 28(1), 107-112.
44. Danner, R.L.; Joiner, K.A.; Rubin, M.; Patterson, W.H.; Johnson, N.; Ayers, K.M.; Parrillo, J.E. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob. Agents Chemother., 1989, 33(9), 1428-1434.
45. Okimura, K.; Ohki, K.; Sato, Y.; Ohnishi, K.; Uchida, Y.; Sakura, N. Chemical conversion of natural polymyxin B and colistin to their N-terminal derivatives. Bull. Chem. Soc. Jpn., 2007, 80(3), 543-552.
46. Sakura, N.; Itoh, T.; Uchida, Y.; Ohki, K.; Okimura, K.; Chiba, K.; Sato, Y.; Sawanishi, H. The contribution of the N-terminal structure of polymyxin B peptides to antimicrobial and lipopolysaccharide binding activity. Bull. Chem. Soc. Jpn., 2004, 77(10), 1915-1924.
47. O'Dowd, H.; Kim, B.; Margolis, P.; Wang, W.; Wu, C.; Lopez, S.L.; Blais, J. Preparation of tetra-Boc-protected polymyxin B nonapeptide. Tetrahedron Lett., 2007, 48(11), 2003-2005.
48. Chihara, S.; Ito, A.; Yahata, M. Chemical synthesis and characterization of n-fatty acyl mono-aminoacyl derivatives of colistin nonapeptide. Agric. Biol. Chem., 1974, 38(10), 1767-1777.
49. Chihara, S.; Ito, A.; Yahata, M. Chemical synthesis, isolation and characterization of α-N-fatty acyl colistin nonapeptide with special reference to the correlation between antimicrobial activity and carbon number of fatty acyl moiety. Agric. Biol. Chem., 1974, 38(3), 521-529.
50. Kimura, Y.; Matsunaga, H.; Vaara, M. Polymyxin B octapeptide and polymyxin B heptapeptide are potent outer membrane permeability-increasing agents. J. Antibiot. (Tokyo), 1992, 45(5), 742-749.
51. Urakawa, H.; Yamada, K.; Komagoe, K.; Ando, S.; Oku, H.; Katsu, T.; Matsuo, I. Structure-activity relationships of bacterial outer-membrane permeabilizers based on polymyxin B heptapeptides. Bioorg. Med. Chem. Lett., 2010, 20(5), 1771-1775.
52. Witzke, N.M.; Heding, H. Broad-spectrum derivatives of polymyxin B and colistin. J. Antibiot. (Tokyo), 1976, 29(12), 1349-1350.
53. Vaara, M.; Siikanen, O.; Apajalahti, J.; Fox, J.; Frimodt-Møller, N.; He, H.; Poudyal, A.; Li, J.; Nation, R.L.; Vaara, T. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob. Agents Chemother., 2010, 54(8), 3341-3346.
54. Vaara, M.; Sader, H.S.; Rhomberg, P.R.; Jones, R.N.; Vaara, T. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. J. Antimicrob. Chemother., 2013, 68(3), 636-639.
55. Vaara, M.; Siikanen, O.; Apajalahti, J.; Frimodt-Møller, N.; Vaara, T. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. J. Antimicrob. Chemother., 2010, 65(5), 942-945.
56. Vaara, M.; Vaara, T. The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubular cells. Int. J. Antimicrob. Agents, 2013, 41(3), 292-293.
57. Katsuma, N.; Sato, Y.; Ohki, K.; Okimura, K.; Ohnishi, K.; Sakura, N. Development of des-fatty acyl-polymyxin B decapeptide analogs with Pseudomonas aeruginosa-specific antimicrobial activity. Chem. Pharm. Bull. (Tokyo), 2009, 57(4), 332-336.
58. Sato, Y.; Shindo, M.; Sakura, N.; Uchida, Y.; Kato, I. Novel desfatty acyl-polymyxin B derivatives with Pseudomonas aeruginosaspecific antimicrobial activity. Chem. Pharm. Bull. (Tokyo), 2011, 59(5), 597-602.
59. Li, J.; Milne, R.W.; Nation, R.L.; Turnidge, J.D.; Smeaton, T.C.; Coulthard, K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J. Antimicrob. Chemother., 2004, 53(5), 837-840.
60. Couet, W.; Gregoire, N.; Gobin, P.; Saulnier, P.J.; Frasca, D.; Marchand, S.; Mimoz, O. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin. Pharmacol. Ther., 2011, 89(6), 875-879.
61. Bergen, P.J.; Li, J.; Rayner, C.R.; Nation, R.L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 2006, 50(6), 1953-1958.
62. Li, J.; Milne, R.W.; Nation, R.L.; Turnidge, J.D.; Coulthard, K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob. Agents Chemother., 2003, 47(4), 1364-1370.
63. Li, J.; Nation, R.L.; Milne, R.W.; Turnidge, J.D.; Coulthard, K. Evaluation of colistin as an agent against multi-resistant Gramnegative bacteria. Int. J. Antimicrob. Agents, 2005, 25(1), 11-25.
64. Ziaka, M.; Markantonis, S.L.; Fousteri, M.; Zygoulis, P.; Panidis, D.; Karvouniaris, M.; Makris, D.; Zakynthinos, E. Combined Intravenous and Intraventricular Administration of Colistin Methanesulfonate in Critically Ill Patients with Central Nervous System Infection. Antimicrob. Agents Chemother., 2013, 57(4), 1938-1940.
65. Jiménez-Mejías, M.E.; Pichardo-Guerrero, C.; Márquez-Rivas, F.J.; Martín-Lozano, D.; Prados, T.; Pachón, J. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur. J. Clin. Microbiol. Infect. Dis., 2002, 21(3), 212-214.
66. Khawcharoenporn, T.; Apisarnthanarak, A.; Mundy, L.M. Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review. Clin. Microbiol. Infect., 2010, 16(7), 888-894.
67. Markantonis, S.L.; Markou, N.; Fousteri, M.; Sakellaridis, N.; Karatzas, S.; Alamanos, I.; Dimopoulou, E.; Baltopoulos, G. Penetration of colistin into cerebrospinal fluid. Antimicrob. Agents Chemother., 2009, 53(11), 4907-4910.
68. Zavascki, A.P.; Goldani, L.Z.; Li, J.; Nation, R.L. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother., 2007, 60(6), 1206-1215.
69. Li, J.; Coulthard, K.; Milne, R.; Nation, R.L.; Conway, S.; Peckham, D.; Etherington, C.; Turnidge, J. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother., 2003, 52(6), 987-992.
70. Garonzik, S.M.; Li, J.; Thamlikitkul, V.; Paterson, D.L.; Shoham, S.; Jacob, J.; Silveira, F.P.; Forrest, A.; Nation, R.L. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother., 2011, 55(7), 3284-3294.
71. Ma, Z.; Wang, J.; Nation, R.L.; Li, J.; Turnidge, J.D.; Coulthard, K.; Milne, R.W. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob. Agents Chemother., 2009, 53(7), 2857-2864.
72. Plachouras, D.; Karvanen, M.; Friberg, L.E.; Papadomichelakis, E.; Antoniadou, A.; Tsangaris, I.; Karaiskos, I.; Poulakou, G.; Kontopidou, F.; Armaganidis, A.; Cars, O.; Giamarellou, H., Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob. Agents Chemother., 2009, 53(8), 3430-3436.
73. Li, J.; Rayner, C.R.; Nation, R.L.; Deans, R.; Boots, R.; Widdecombe, N.; Douglas, A.; Lipman, J. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob. Agents Chemother., 2005, 49(11), 4814-4815.
74. Marchand, S.; Frat, J.P.; Petitpas, F.; Lemaitre, F.; Gobin, P.; Robert, R.; Mimoz, O.; Couet, W. Removal of colistin during intermittent haemodialysis in two critically ill patients. J. Antimicrob. Chemother., 2010, 65(8), 1836-1837.
75. Azad, M.A.; Huang, J.X.; Cooper, M.A.; Roberts, K.D.; Thompson, P.E.; Nation, R.L.; Li, J.; Velkov, T. Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoprotein. Biochem. Pharmacol., 2012, 84(3), 278-291.
76. Kunin, C.M.; Bugg, A. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J. Infect. Dis., 1971, 124(4), 394-400.
77. Craig, W.A.; Kunin, C.M. Significance of serum protein and tissue binding of antimicrobial agents. Annu. Rev. Med., 1976, 27, 287-300.
78. Mehta, R.T. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Antimicrob. Agents Chemother., 1996, 40(8), 1893-1902.
79. Takemoto, K.; Yamamoto, Y.; Ueda, Y.; Sumita, Y.; Yoshida, K.; Niki, Y. Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J. Antimicrob. Chemother., 2004, 53(2), 311-317.
80. Anderson, M.; Omri, A. The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Deliv., 2004, 11(1), 33-39.
81. Alipour, M.; Halwani, M.; Omri, A.; Suntres, Z.E. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gramnegative bacterial strains. Int. J. Pharm., 2008, 355(1-2), 293-298.
82. Wallace, S.J.; Nation, R.L.; Li, J.; Boyd, B.J. Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies. J. Pharm. Sci., 2013, 102(5), 1578-1587.
83. Barnett, M.; Bushby, S.R.; Wilkinson, S. Sodium sulphomethyl derivatives of polymyxins. Br. J. Pharmacol. Chemother., 1964, 23, 552-574.
84. Moestrup, S.K.; Cui, S.; Vorum, H.; Bregengård, C.; Bjørn, S.E.; Norris, K.; Gliemann, J.; Christensen, E.I. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J. Clin. Invest., 1995, 96(3), 1404-1413.
85. Zavascki, A.P.; Goldani, L.Z.; Cao, G.; Superti, S.V.; Lutz, L.; Barth, A.L.; Ramos, F.; Boniatti, M.M.; Nation, R.L.; Li, J. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin. Infect. Dis., 2008, 47(10), 1298-1304.
86. Hoeprich, P.D. The polymyxins. Med. Clin. North Am., 1970, 54(5), 1257-1265.
87. McQuillen, M.P.; Cantor, H.A.; O'Rourke, J.R. Myasthenic syndrome associated with antibiotics. Trans. Am. Neurol. Assoc., 1967, 92, 163-167.
88. Viswanath, D.V.; Jenkins, H.J. Neuromuscular block of the polymyxin group of antibiotics. J. Pharm. Sci., 1978, 67(9), 1275-1280.
89. Singh, Y.N.; Marshall, I.G.; Harvey, A.L. Pre- and postjunctional blocking effects of aminoglycoside, polymyxin, tetracycline and lincosamide antibiotics. Br. J. Anaesth., 1982, 54(12), 1295-1306.
90. Falagas, M.E.; Kasiakou, S.K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care, 2006, 10(1), R27.
91. Inoue, A.; Shoji, A. Allergic contact dermatitis from colistin. Contact Dermatitis, 1995, 33(3), 200.
92. Van Bambeke, F.; Lambert, D.M.; Mingeot-Leclercq, M.P.; Tulkens, P.M. In Infectious Diseases, 2nd ed. Cohen, J.; Powderly, W.G., Eds.; Mosby-Elsevier: Edinburgh, 2004; Vol. 188, p 1730.
93. Michalopoulos, A.; Papadakis, E. Inhaled anti-infective agents: emphasis on colistin. Infection, 2010, 38(2), 81-88.
94. de Gouw, N.E.; Crul, J.F.; Vandermeersch, E.; Mulier, J.P.; van Egmond, J.; Van Aken, H. Interaction of antibiotics on pipecuronium-induced neuromuscular blockade. J. Clin. Anesth., 1993, 5(3), 212-215.
95. Decolin, D.; Leroy, P.; Nicolas, A.; Archimbault, P. Hyphenated liquid chromatographic method for the determination of colistin residues in bovine tissues. J. Chromatogr. Sci., 1997, 35(12), 557-564.
96. Le Brun, P.P.; de Graaf, A.I.; Vinks, A.A. High-performance liquid chromatographic method for the determination of colistin in serum. Ther. Drug Monit., 2000, 22(5), 589-593.
97. Ma, Z.; Wang, J.; Gerber, J.P.; Milne, R.W. Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2008, 862(1-2), 205-212.
98. Wan, E.C.; Ho, C.; Sin, D.W.; Wong, Y.C. Detection of residual bacitracin A, colistin A, and colistin B in milk and animal tissues by liquid chromatography tandem mass spectrometry. Anal. Bioanal. Chem., 2006, 385(1), 181-188.
99. Mitaka, C.; Tomita, M. Polymyxin B-immobilized fiber column hemoperfusion therapy for septic shock. Shock, 2011, 36(4), 332-338.
100. Shimokawa, K.; Takakuwa, R.; Taya, K.; Wada, Y.; Yamazaki, N.; Murata, M.; Hirata, K.; Masuno, T.; Yokota, H.; Ishii, F. Adsorption of various antimicrobial agents to endotoxin removal polymyxin-B immobilized fiber (Toraymyxin® ). Colloids Surf. B. Biointerfaces, 2012, 90, 58-61.
101. 2+ environments. J. Bacteriol., 1997, 179(22), 7040-7045.
102. Velkov, T.; Thompson, P.E.; Nation, R.L.; Li, J. Structure - activity relationships of polymyxin antibiotics. J. Med. Chem., 2010, 53(5), 1898-1916.
103. Rifkind, D. Prevention by polymyxin B of endotoxin lethality in mice. J. Bacteriol., 1967, 93(4), 1463-1464.
104. Bannatyne, R.M.; Harnett, N.M.; Lee, K.Y.; Biggar, W.D. Inhibition of the biologic effects of endotoxin on neutrophils by polymyxin B sulfate. J. Infect. Dis., 1977, 136(4), 469-474.
105. Shoji, H.; Tani, T.; Hanasawa, K.; Kodama, M. Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application. Ther. Apher., 1998, 2(1), 3-12.
106. Tani, T.; Hanasawa, K.; Endo, Y.; Yoshioka, T.; Kodama, M.; Kaneko, M.; Uchiyama, Y.; Akizawa, T.; Takahasi, K.; Sugai, K. Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilized column. Artif Organs, 1998, 22(12), 1038-1044.
107. Giamarellos-Bourboulis, E.J.; Karnesis, L.; Giamarellou, H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis., 2002, 44(3), 259-263.
108. Aoki, N.; Tateda, K.; Kikuchi, Y.; Kimura, S.; Miyazaki, C.; Ishii, Y.; Tanabe, Y.; Gejyo, F.; Yamaguchi, K. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J. Antimicrob. Chemother., 2009, 63(3), 534-542.
109. Pachón-Ibáñez, M.E.; Docobo-Pérez, F.; López-Rojas, R.; Domínguez-Herrera, J.; Jiménez- Mejías, M.E.; García-Curiel, A.; Pichardo, C.; Jiménez, L.; Pachón, J. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother., 2010, 54(3), 1165-1172.
110. Pankey, G.A.; Ashcraft, D.S. Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis., 2011, 70(4), 561-564.
111. Ozbek, B.; Mataraci, E. In vitro effectiveness of colistin, tigecycline and levofloxacin alone and combined with clarithromycin and/or heparin as lock solutions against embedded Acinetobacter baumannii strains. J. Antimicrob. Chemother., 2013, 68(4), 827-830.
112. Jernigan, M.G.; Press, E.G.; Nguyen, M.H.; Clancy, C.J.; Shields, R.K. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother., 2012, 56(6), 3395-3398.
113. Lee, G.C.; Burgess, D.S. Polymyxins and Doripenem Combination Against KPC-Producing Klebsiella pneumoniae. J. Clin. Med. Res., 2013, 5(2), 97-100.
114. Vidaillac, C.; Benichou, L.; Duval, R.E. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother., 2012, 56(9), 4856-4861.
115. Zhai, B.; Zhou, H.; Yang, L.; Zhang, J.; Jung, K.; Giam, C.Z.; Xiang, X.; Lin, X. Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J. Antimicrob. Chemother., 2010, 65(5), 931-938.
116. Zeidler, U.; Bougnoux, M.E.; Lupan, A.; Helynck, O.; Doyen, A.; Garcia, Z.; Sertour, N.; Clavaud, C.; Munier-Lehmann, H.; Saveanu, C.; d'Enfert, C. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. J. Antimicrob. Chemother., 2013, 68(6), 1285-1296.
117. Ikai, Y.; Oka, H.; Hayakawa, J.; Kawamura, N.; Mayumi, T.; Suzuki, M.; Harada, K. Total structures of colistin minor components. J. Antibiot. (Tokyo), 1998, 51(5), 492-498.